Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 316 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole Clear all
Completed Phase 3 Interventional

Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill

NCT00045799
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding
Interventions
Omeprazole sodium bicarbonate immediate release PWD/FS, Cimetidine IV
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
16 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
58
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 17, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

NCT03234699
View directory record Official record
Conditions
Healthy
Interventions
Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

NCT01135472
View directory record Official record
Conditions
Healthy
Interventions
Esomeprazole Magnesium
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430
View directory record Official record
Conditions
Healthy
Interventions
Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Placebo, Omeprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

NCT01980095
View directory record Official record
Conditions
Dyspepsia, Helicobacter Pylori Infection
Interventions
RHB-105, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Anaheim, California • Chino, California • Jupiter, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 17, 2026, 7:15 AM EDT
Recruiting Phase 1 Interventional

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

NCT06366243
View directory record Official record
Conditions
Healthy Participants
Interventions
Emraclidine, Esomeprazole
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 17, 2026, 7:15 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Anti-reflux Control to Decrease Post Tonsillectomy Pain

NCT01777854
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Throat Pain
Interventions
Omeprazole
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Omeprazole Decrease Intestinal Calcium Absorption?

NCT00582972
View directory record Official record
Conditions
Osteoporosis, Achlorhydria, GERD, Hip Fracture
Interventions
Omeprazole
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

NCT01218620
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

NCT04201197
View directory record Official record
Conditions
Drug-Interactions
Interventions
Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370525
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Sacramento, California • Seminole, Florida • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 17, 2026, 7:15 AM EDT
Recruiting Phase 2 Interventional

Esomeprazole and Radiation Induced Esophagitis

NCT06120803
View directory record Official record
Conditions
Radiation Esophagitis, Locally Advanced Lung Carcinoma
Interventions
Esomeprazole 40 mg
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 7:15 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery

NCT00361985
View directory record Official record
Conditions
Anastomotic Stricture, Morbid Obesity
Interventions
Esomeprazole
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

NCT00420615
View directory record Official record
Conditions
Solid Tumors
Interventions
Patupilone and Omeprazole, Patupilone + Midalzolam
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT02647086
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

NCT04425902
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 200 mg, Caffeine 200 mg, Metoprolol 100 mg, Montelukast 10 mg, Flurbiprofen 100 mg, Omeprazole 40 mg, Midazolam 5 mg (2.5 mL), Digoxin 0.25 mg, Pravastatin 40 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 17, 2026, 7:15 AM EDT
Withdrawn Phase 2 Interventional

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

NCT03488147
View directory record Official record
Conditions
Dysphagia, GERD, Degenerative Joint Disease
Interventions
Esomeprazole, Placebo Oral Tablet
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 17, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Omeprazole and PA21

NCT01452906
View directory record Official record
Conditions
Healthy
Interventions
PA21 and Omeprazole with food, No PA21; Omeprazole with food, PA21 with food, Omeprazole 2hrs later
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 17, 2026, 7:15 AM EDT